Tech Company Financing Transactions
TRexBio Funding Round
On 6/23/2021, TRexBio raised $59 million in Series A funding from Alexandria Venture Investments, Eli Lilly and Company and Johnson & Johnson Development Corporation.
Transaction Overview
Company Name
Announced On
6/23/2021
Transaction Type
Venture Equity
Amount
$59,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to expand the company's unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Johnston Erwin
Chief Medical Officer
Ovid Trifan
Chief Scientific Officer
Melanie Kleinschek
VP - Bus. Development
Laura Berner
Browse more venture capital transactions:
Prev: 6/23/2021: Neurona Therapeutics venture capital transaction
Next: 6/23/2021: Songtradr venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs